Table III.
Characteristics of patients who underwent surgical treatment for prostate cancer (radical prostatectomy) in pre-COVID and COVID period
Variable | Overall n (%)/mean (IQR) | Pre-COVID n (%)/mean (IQR) | COVID n (%)/mean (IQR) | P-value | |
---|---|---|---|---|---|
Age | 65.1 (8) | 65.3 (8) | 64.9 (8) | 0.59 | |
ASA: | 1 | 35 (9%) | 20 (10.1%) | 15 (7.9%) | 0.73 |
2 | 284 (73%) | 142 (71.4%) | 142 (74.7%) | ||
3 | 69 (17.7%) | 36 (18.1%) | 33 (17.4%) | ||
≥ 4 | 1 (0.3%) | 1 (0.5%) | 0 (0%) | ||
Hgb [g/dl] | 14.5 (1.6) | 14.6 (1.6) | 14.5 (1.6) | 0.76 | |
Laparoscopy | 307 (78.9%) | 158 (83.2%) | 149 (74.9%) | 0.048 | |
eLND | 201 (48.3%) | 102 (53.7%) | 99 (49.8%) | 0.48 | |
PSA [ng/ml] | 12.3 (8.1) | 12.2 (7) | 12.4 (9.3) | 0.81 | |
Grade group: | I | 157 (41.3%) | 86 (46%) | 71 (36.7%) | 0.028 |
II | 107 (28.2%) | 56 (30%) | 51 (26.4%) | ||
III | 62 (16.3%) | 24 (12.8%) | 38 (19.7%) | ||
IV | 43 (11.3%) | 14 (7.5%) | 29 (15%) | ||
V | 11 (2.9%) | 7 (3.7%) | 4 (2.1%) | ||
DRE (+) | 207 (54.5%) | 90 (47.4%) | 117 (61.6%) | 0.007 | |
cT: | cT1 | 140 (36%) | 77 (40.5%) | 63 (31.2%) | 0.13 |
cT2 | 206 (53%) | 91 (47.9%) | 115 (57.8%) | ||
≥ cT3 | 43 (11.1%) | 22 (11.6%) | 21 (10.6%) | ||
LOH | 5.8 (2) | 5.7 (3) | 5.8 (3) | 0.084 |
ASA – American Society of Anesthesiologists score, Hgb – haemoglobin, eLND- extended lymph node dissection, PSA – prostate-specific antigen, DRE – digital rectal examination, cT – clinical local staging, LOH – length of hospitalisation.